UBE3A encodes UBE3A, an E3 ubiquitin-protein ligase that catalyzes the transfer of ubiquitin to substrate proteins, marking them for degradation via the proteasome or for non-degradative signaling. The gene is uniquely subject to genomic imprinting — it is expressed exclusively from the maternal allele in neurons, while the paternal allele is silenced by a long antisense transcript (UBE3A-ATS). This parent-of-origin expression pattern means that loss of the maternal UBE3A copy leads to Angelman syndrome, while duplication of the paternal copy is associated with autism spectrum disorder.
UBE3A is critical for synaptic function, learning, and memory. Its key neuronal substrate is Arc (activity-regulated cytoskeleton-associated protein), which is essential for AMPA receptor trafficking and synaptic plasticity. Loss of UBE3A leads to Arc accumulation, disrupted synaptic scaling, and impairments in learning[@mabb2011][@greer2010].
| Property |
Value |
| Gene Symbol |
UBE3A |
| Chromosomal Location |
15q11.2 |
| Genomic Coordinates |
chr15:25,310,000-25,420,000 (GRCh38) |
| Gene Length |
~120 kb |
| Number of Exons |
11 coding exons |
| Protein Length |
865 amino acids |
| Protein Class |
E3 ubiquitin ligase (HECT family) |
| Expression |
Brain (neurons), widespread peripheral tissue |
| Imprinting |
Maternal expression in neurons; biallelic in most peripheral tissues |
| OMIM |
601623 |
| UniProt |
Q05086 |
¶ Structure and Function
¶ Protein Domains
UBE3A contains several key functional regions:
- HERC2 interaction domain — mediates binding to HERC2, which regulates UBE3A subcellular localization
- HECT domain — the catalytic domain (~350 aa) that transfers ubiquitin to substrates
- SH3 domain (variant isoforms) — protein-protein interaction motif
- Nuclear localization signals — multiple NLS sequences for nuclear/cytoplasmic shuttling
UBE3A functions as a substrate-specific E3 ligase. Its canonical activity involves:
- E1 activation — UBE3A receives ubiquitin from the E1 activating enzyme
- E2 transfer — ubiquitin is transferred to a cysteine residue in the UBE3A HECT domain
- E3 ligation — UBE3A catalyzes transfer of ubiquitin to lysine residues on substrate proteins
Ubiquitination can result in:
- Proteasomal degradation (K48-linked chains)
- Lysosomal degradation (K63-linked chains)
- Non-degradative signaling (monoubiquitination, other linkages)
The neuron-specific imprinting of UBE3A is controlled by the imprinted locus on chromosome 15q11.2:
- Maternal allele: expressed in neurons — the active copy
- Paternal allele: silenced by UBE3A-ATS (antisense transcript) — the silent copy
- Non-neuronal tissues: UBE3A is biallelically expressed (paternal copy is active)
This tissue-specific imprinting explains why Angelman syndrome results from loss of maternal UBE3A even though the paternal allele is intact — it is simply silenced in the relevant tissue (neurons).
Loss of maternal UBE3A leads to a cascade of downstream effects:
- Arc accumulation — Arc (activity-regulated cytoskeleton-associated protein) is the best-characterized UBE3A substrate. Without UBE3A-mediated ubiquitination, Arc accumulates in neurons, disrupting AMPA receptor trafficking and synaptic plasticity[@greer2010]
- Proteasome dysfunction — impaired protein turnover affects synaptic protein composition
- Synaptic scaling abnormalities — homeostatic plasticity mechanisms are disrupted
- Calcium signaling defects — altered calmodulin-dependent kinase pathways
- Mitochondrial dysfunction — indirect metabolic consequences affecting neuronal energy[@santos2018]
Preclinical studies in Ube3a mouse models demonstrate that:
- Earlier intervention yields better outcomes
- There is a "critical period" for cerebellar plasticity (approximately weeks 3-6 in mice, corresponding to early childhood in humans)
- Direct ASIC delivery of UBE3A to young mice can rescue behavioral phenotypes; delivery to older mice shows more limited effects
| Disorder |
Mechanism |
Key Features |
| Angelman syndrome |
Maternal UBE3A loss (deletion, mutation, imprinting) |
Severe intellectual disability, ataxia, happy demeanor, seizures |
| Angelman syndrome ( imprinting defect) |
Paternal-only UBE3A (bipaternal inheritance) |
Same phenotype as deletion/mutation |
| 15q11.2-q13 duplication syndrome |
Paternal UBE3A duplication |
Autism, intellectual disability, seizures |
| Paternal UBE3A triplication |
Extra paternal UBE3A copy |
More severe autism phenotype |
- ~70% of Angelman cases: 5-7 Mb maternal deletion of 15q11.2-q13 — typically most severe
- ~10-15%: paternal uniparental disomy (UPD) — same phenotype but no deletion
- ~5-10%: UBE3A mutation — same phenotype
- ~5%: imprinting center defect — same phenotype
- Patients with deletions often have more severe epilepsy and motor impairment than those with mutations
GTX-102 (GeneTx/Ultragenyx) — AAV9-delivered antisense oligonucleotide targeting UBE3A-ATS to reactivate the silenced paternal allele. By suppressing the antisense transcript, GTX-102 aims to "unsilence" the paternal UBE3A, restoring functional protein levels. Currently in Phase 1/2 clinical trials. See GTX-102 clinical trial page.
The paternal UBE3A gene is intact but silenced by the UBE3A-ATS antisense transcript, which spans the imprinted locus and blocks paternal expression. ASOs targeting UBE3A-ATS can:
- Degrade the antisense transcript via RNase H recruitment
- Restore paternal UBE3A mRNA expression
- Produce functional UBE3A protein from the previously silent allele
- Gene replacement: AAV-delivered functional UBE3A — challenged by gene size (~2.6 kb coding)
- Protein replacement: Not feasible due to size and blood-brain barrier
- Small molecule activation: Topoisomerase inhibitors (doxorubicin) can unsilence paternal UBE3A in vitro but are too toxic for clinical use
- Epigenetic editing: CRISPR-based approaches to modify imprinting center methylation — preclinical
Angelman syndrome presents a unique therapeutic window challenge:
- Early intervention: Critical period for synaptic development and cerebellar plasticity suggests treatment should be initiated as early as possible
- Chronic treatment: The paternal allele silencing mechanism is persistent, so ongoing ASO therapy may be required
- ASO delivery: Intrathecal (IT) or intracerebroventricular (ICV) delivery required to achieve sufficient CNS concentrations
¶ Research and Open Questions
- Substrate identification — what are all the relevant UBE3A substrates in neurons beyond Arc?
- Optimal timing — when does the critical period close, and can it be extended?
- ASO durability — how often must GTX-102 be dosed to maintain therapeutic effect?
- Biomarkers — what pharmacodynamic markers indicate successful UBE3A reactivation?
- Delivery optimization — can non-invasive routes achieve sufficient CNS penetration?
- Imprinting boundary — what determines the neuronal specificity of paternal silencing?
- [@mabb2011] Angelman syndrome: insights into genomic imprinting and neurodevelopmental disorders
- [@greer2010] The Angelman Syndrome protein UBE3A regulates synaptic development by targeting Arc for degradation
- [@santos2018] Mitochondrial dysfunction in Angelman syndrome
- [@williams1995] Angelman syndrome: consensus for diagnostic criteria